ArticleFrontiers in aging neuroscience2026
Statin use and all-cause mortality in critically ill ischemic stroke patients: a time-dependent Cox analysis with external validation highlighting enhanced survival benefits in dementia subgroups.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ischemic stroke is a leading cause of mortality and disability, but the effect of statins on survival in critically ill patients, especially those with dementia, remains unclear. Methods: This retrospective cohort study analyzed 1,964 patients from MIMIC-IV and validated findings in 4,255 external cases. Time-dependent Cox, IPTW, and PSM were applied. Results: Statin use was significantly associated with reduced mortality at 30, 90, 180 days, and 1 year, though the effect attenuated over time. A significant statin-dementia interaction was observed, with greater benefit in dementia patients (adjusted HR = 0.548; NNT = 7 vs. 13). The strongest protection occurred immediately post-admission (74.1% risk reduction) and waned by 1 year. Results were robust in sensitivity and external validation. Discussion: In conclusion, statin therapy improves short-to-medium-term survival in critically ill ischemic stroke patients, with potential additional benefits observed in those with dementia. These findings support early statin use and suggest dementia as a potential effect modifier, though prospective validation with standardized cognitive assessments is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.